Evidence map›Paper›PMID 40595916›Full record

ArticleScientific reports2025

High dynamic range capillary electrophoresis method for sensitive detection of low-frequency driver mutations.

Nobue Tamamura, Yoshihiko Hagiwara, Hirokazu Kato, Yusuke Ono, Kenji Takahashi, Kazuya Koyama, Hiroki Sato, Tetsuhiro Okada, Hidemasa Kawabata, Yu Ohtaki and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nobue TamamuraDepartment of Advanced Genomic Community Healthcare, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
Yoshihiko HagiwaraNaka Diagnostic Products Division, Bio Systems Design 1st Department, Hitachi High-Tech Corporation, Toranomon Hills Business Tower, 1-17-1 Toranomon, Minato-ku, Tokyo, 105-6409, Japan.
Hirokazu KatoNaka Diagnostic Products Division, Bio Systems Design 1st Department, Hitachi High-Tech Corporation, Toranomon Hills Business Tower, 1-17-1 Toranomon, Minato-ku, Tokyo, 105-6409, Japan. hirokazu.kato.gz@hitachi-hightech.com.
Yusuke OnoDepartment of Advanced Genomic Community Healthcare, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
Kenji TakahashiDepartment of Advanced Genomic Community Healthcare, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
Kazuya KoyamaDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Hiroki SatoDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Tetsuhiro OkadaDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Hidemasa KawabataDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Yu OhtakiDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Chiho MaedaInstitute of Biomedical Research, Sapporo-Higashi Tokushukai Hospital, Sapporo, Hokkaido, 065-0033, Japan.
Miyuki MoriInstitute of Biomedical Research, Sapporo-Higashi Tokushukai Hospital, Sapporo, Hokkaido, 065-0033, Japan.
Shin-Ichi ChibaCenter for Advanced Research and Education, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, Hokkaido, 078-8510, Japan.
Kenzui TaniueDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Takashi AnazawaHitachi, Ltd., Tokyo, 185-8601, Japan.
Ryoji InabaNaka Diagnostic Products Division, Bio Systems Design 1st Department, Hitachi High-Tech Corporation, Toranomon Hills Business Tower, 1-17-1 Toranomon, Minato-ku, Tokyo, 105-6409, Japan.
Yusuke MizukamiDepartment of Advanced Genomic Community Healthcare, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan. mizu@asahikawa-med.ac.jp.

Funding

Japan Society for the Promotion of Science 23K06759Japan Society for the Promotion of Science 24K02431
6 · The paper itself

Abstract

Cancer genomics aims to personalize treatments by identifying genetic abnormalities in cancer cells. However, current analytical techniques face limitations in simplicity and cost-effectiveness. To address these issues, we developed an enhanced capillary gel electrophoresis (CE) sequencer using a fluorescence-acquisition technique called "HiDy" (High Dynamic range) (HiDy-CE). The HiDy-CE reduces the hardware binning region size and increases the number of regions on a charge-coupled device image sensor, expanding the dynamic range and reducing saturation risk. By applying the multi-base primer extension method to the HiDy-CE with control DNA containing known mutations, we detected variant allele frequencies (VAFs) as low as 0.5% for major KRAS hotspot mutation at codon 12 and 13. With 10 ng of DNA from small tissues obtained via fine-needle biopsy from patients with suspected pancreaticoduodenal tumors, HiDy-CE produced equivalent VAFs in KRAS compared with targeted amplicon sequencing. This demonstrated the world's first capability of detecting mutations below 1% on CE using pathological specimens, leveraging its wide dynamic range. With only 2 ng of input DNA, the HiDy-CE provided results highly concordant with digital PCR with minimal non-specific noise. These findings underscore the HiDy-CE's potential for sensitive detection of oncogenes such as KRAS, facilitating pre-testing before comprehensive genome profiling.

Indexed as

MutationProto-Oncogene Proteins p21(ras)DNA Mutational AnalysisElectrophoresis, CapillaryGene FrequencyHumansPancreatic NeoplasmsKRAS protein, humanProto-Oncogene Proteins p21(ras)Capillary gel electrophoresisDynamic rangeFragment analysisHiDyKRASLow-frequency mutation

Identifiers

PMID40595916
PMCPMC12218273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.